Kapil Cotex Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/08/2025 ,inter alia, to consider and approve the Proposal on Change of Name ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kapil Cotex Limited (BSE: 512036) has called a board meeting on 28 August 2025 to consider a major rebranding — changing the company's name to Skybiotech Healthcare Limited or Skybiotech Pharmaceuticals Limited, subject to approval from the Registrar of Companies (CRC), Delhi. The board will also consider altering the main object clause of its Memorandum of Association, suggesting a shift in business focus likely from textiles to healthcare/pharma. Other items on the agenda include increasing authorised share capital from Rs 2 crore to Rs 5 crore (a 2.5x jump), appointing Mr. Vijay Sitaram Chitlange as a Non-Executive Independent Director, and onboarding M/s. SM Dhumal & Associates as Secretarial Auditor. The board will also approve the 42nd Annual Report for FY 2024-25, fix the AGM date, and adopt a new set of MOA and AOA aligned with the Companies Act 2013.
The name change and main-object clause alteration strongly hint at a business pivot from cotton/textiles into healthcare or pharmaceuticals, which is a significant strategic shift for shareholders. The proposed 2.5x increase in authorised share capital signals the company is likely preparing to raise fresh funds to fund this new business direction, which could lead to dilution in the future.